Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jakafi (Ruxolitinib) for Symptom Control in CLL
NCT02131584Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2014
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in chronic lymphocytic leukemia (CLL), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2014; status: active, not recruiting.
02
Drugs
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02131584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02131584.